Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | CPA1 | P15085 | 3/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.42 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2648456 | 1.00 | MME (0.50) | MMEACECPA1ACE2FFAR1 | |
| SCHEMBL1418773 | 0.90 | CYP2C19 (0.47) | MMEACECPA1ACE2METAP2 | |
| SCHEMBL1418768 | 0.90 | CYP2C19 (0.47) | MMEACECPA1ACE2METAP2 | |
| SCHEMBL2647021 | 0.87 | ROCK2 (0.43) | MMEACECPA1ACE2APP | |
| SCHEMBL2647246 | 0.87 | MKNK1 (0.47) | MMEACECPA1ACE2 | |
| SCHEMBL2648711 | 0.84 | MME (0.46) | MMEACECPA1ACE2FFAR1 | |
| SCHEMBL2647518 | 0.84 | NPY5R (0.53) | FFAR1ALDH1A1GPR88METAP2METAP1 | |
| SCHEMBL8496508 | 0.83 | CYP2C19 (0.50) | MEN1ALDH1A1KMT2A | |
| SCHEMBL11879793 | 0.83 | CYP2C19 (0.50) | MEN1ALDH1A1KMT2A | |
| SCHEMBL2647993 | 0.83 | PPARG (0.50) | ALDH1A1METAP2METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1282611-B1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2004-10-20 | — | — | EP | disclosed |
| EP-1282611-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-12 | — | — | EP | disclosed |
| US-6384220-B2 | ANTIDIABETIC AGENTS INCREASING THE EXPRESSION OF GLUCOKINASE (GK) TO IMPROVE GLUCOSE TOLERANCE; INCREASE IN GLUCOSE EXPOSURE COUPLED THROUGH GK IN BETA-CELLS TO INCREASE INSULIN SECRETION AND IN HEPATOCYTES TO INCREASE GLYCOGEN DEPOSITION | HOFFMANN-LA ROCHE INC. | 2002-05-07 | — | — | US | disclosed |
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | HOFFMANN-LA ROCHE INC. | 2002-01-03 | — | — | US | disclosed |
| WO-2001085706-A1 | SUBSTITUTED PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002190-A1 | Para-aryl or heterocyclic substituted phenyl glucokinase activators | GCKR, GCK, PDXK | MME 1379/4885ACE 147/4885CPA1 1642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.